How MK-677 Affects Sodium and Fluid Retention

MK-677 (ibutamoren) is a ghrelin receptor agonist that produces sustained, continuous growth hormone elevation over 24 hours because of its long half-life. The downstream GH-IGF-1 axis activation is what drives sodium retention, not MK-677 itself.

Kamenicky et al. (2008, PMID 18388193) identified the epithelial sodium channel (ENaC) in the renal collecting duct as the key mediator of GH-induced sodium retention in acromegaly. The mechanism extends to any condition that produces sustained supraphysiological GH:

1. Direct ENaC upregulation: GH increases ENaC expression and activity in the principal cells of the collecting duct, increasing sodium reabsorption.
2. RAAS activation: GH activates the renin-angiotensin system (Ho and Weissberger, 1990, PMID 2405233), raising aldosterone alongside angiotensin II. This compounds the ENaC signal.
3. Insulin resistance contribution: MK-677 worsens insulin resistance, and hyperinsulinaemia independently promotes renal sodium retention. This is a secondary but real mechanism.

The retention is sodium-driven, water follows. Loop diuretics like furosemide are largely ineffective here because the sodium escapes downstream of the loop. The correct intervention is an ARB (telmisartan), which blocks the RAAS contribution and indirectly reduces ENaC activity.

On standard MK-677 doses (10 to 25 mg/day oral):

• Serum sodium typically stays within normal range (135 to 145 mmol/L) because the kidney retains water along with sodium, keeping concentration stable
• Total body sodium and water both rise, producing visible fluid retention
• Weight gain of 2 to 4 kg in the first two weeks is typical, mostly fluid
• Subcutaneous bloat, ring tightness, ankle swelling all reflect the sodium-driven volume expansion
• Blood pressure typically rises 5 to 10 mmHg systolic on chronic use

Timing:

• Onset within 3 to 7 days of starting
• Peak retention by week 2 to 3
• Partial accommodation over 4 to 8 weeks as the body adjusts; full resolution only occurs after stopping MK-677
• Resolution typically takes 7 to 14 days off-cycle

Baseline before starting MK-677: Pull a basic metabolic panel (sodium, potassium, creatinine, eGFR), plus fasting glucose and HbA1c since MK-677 also worsens insulin resistance. Document baseline blood pressure and morning weight.

During use:

• Daily morning weight tracking for the first two weeks catches retention early
• Repeat BMP at week 4 if blood pressure rises or if visible fluid retention is severe
• Sodium itself rarely moves outside normal range; the value of the BMP is documenting creatinine and potassium trends if an ARB is added

Action thresholds:

• Weight gain over 5 kg in two weeks of MK-677 with visible bloat is excessive; reduce dose or stop
• Blood pressure rising above 140/90 on MK-677 is the cue to add telmisartan, not to push through
• Resting heart rate rising above 80 bpm suggests the volume load is straining the heart; reduce dose

Reducing the retention without stopping MK-677:

• Lower the dose: 10 mg/day produces meaningfully less retention than 25 mg/day. Most users see 80 percent of the IGF-1 benefit at half the dose
• Time the dose to evening only: the GH pulse during sleep is the most useful for body composition and recovery
• Add telmisartan 20 to 40 mg in the morning if BP rises; this targets the RAAS contribution and has the bonus PPAR-gamma effect that helps the MK-677-induced insulin resistance
• Sodium restriction (under 2 g/day) reduces visible bloat but doesn't change the underlying mechanism
• Avoid stacking with growth hormone, exogenous insulin, or oral 17-AAs; all three drive sodium retention through overlapping pathways

When to stop:

• Persistent BP above 150/95 despite telmisartan 80 mg
• Worsening symptoms of insulin resistance: dark patches on skin, increased thirst, fasting glucose above 110 mg/dL (6.1 mmol/L) or HbA1c above 5.7 percent
• New-onset peripheral edema severe enough to require diuretic use

Diuretic caveat: Loop diuretics fail here because GH-driven sodium retention escapes downstream of the loop of Henle. Thiazides are marginally better but also limited. The mechanistically correct intervention is the ARB.